Published in Immunotherapy Weekly, August 6th, 2008
Cenix will apply its well-established expertise in combining high throughput applications of small RNA-based gene silencing with high content phenotypic analyses in cultured human cells. The company will thereby screen libraries of synthetic miRNA modulators designed and produced by Regulus, using multi-parametric assays to identify novel lead molecules offering highest therapeutic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.